Some parts of the portal may cause error messages or display incorrectly due to the transition to a new provider of trading data

RCKT - Rocket Pharmaceuticals Inc


IEX Last Trade
18.81
0.030   0.159%

Share volume: 617,045
Last Updated: Fri 30 Aug 2024 10:00:00 PM CEST
Research and Development in Biotechnology (except Nanobiotechnology): 0.21%

PREVIOUS CLOSE
CHG
CHG%

$18.78
0.03
0.16%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Fundamental analysis
9%
Profitability 8%
Dept financing 6%
Liquidity 50%
Performance 0%
Company vs Stock growth
vs
Performance
5 Days
1.40%
1 Month
-23.25%
3 Months
-12.12%
6 Months
-35.07%
1 Year
17.15%
2 Year
22.88%
Key data
Stock price
$18.81
P/E Ratio 
0.00
DAY RANGE
N/A - $19.08
EPS 
$0.00
52 WEEK RANGE
$15.27 - $32.53
52 WEEK CHANGE
$0.18
MARKET CAP 
1.716 B
YIELD 
N/A
SHARES OUTSTANDING 
91.014 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/04/2024
BETA 
1.54
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$713,978
AVERAGE 30 VOLUME 
$757,072
Company detail
CEO: Gaurav Shah
Region: US
Website: https://www.rocketpharma.com/
Employees: 205
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services

rocket pharmaceuticals, ltd is a biotechnology company focused on seeking cures through molecular and gene therapy. we are developing first-in-class treatments for patients with rare and often devastating orphan diseases using a lentiviral-based gene therapy approach. we have developed rewarding partnerships with a number of leading international research institutions as well as with centers of manufacturing and cell processing expertise, while building an internal team to drive the research, development, clinical and regulatory programs. ultimately we aim to launch and globally commercialize innovative gene therapies in disease areas with high unmet need. for more information, please visit www.rocketpharma.com.

Recent news